Publikationen in Zusammenarbeit mit Forschern von Heinrich Heine University Düsseldorf (38)

2024

  1. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023

    Transplant Infectious Disease, Vol. 26, Núm. 1

2023

  1. COVID19-associated new-onset movement disorders: a follow-up study

    Journal of Neurology, Vol. 270, Núm. 5, pp. 2409-2415

  2. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

    Bone Marrow Transplantation, Vol. 58, Núm. 10, pp. 1084-1088

2022

  1. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

    Frontiers in Immunology, Vol. 13

  2. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

    The oncologist, Vol. 27, Núm. 7, pp. e561-e570

  3. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

    Frontiers in Immunology, Vol. 13

2021

  1. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537

  2. Artificial intelligence extension of the OSCAR-IB criteria

    Annals of Clinical and Translational Neurology, Vol. 8, Núm. 7, pp. 1528-1542

  3. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

    Journal of the National Cancer Institute, Vol. 113, Núm. 4, pp. 443-452

  4. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

    Leukemia, Vol. 35, Núm. 3, pp. 835-849

  5. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491

2020

  1. 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. S713-S723

  2. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8

2019

  1. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    Critical Reviews in Oncology/Hematology, Vol. 134, pp. 39-45

2018

  1. Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus

    Scientific Reports, Vol. 8, Núm. 1

  2. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415

  3. Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer

    Oncotarget, Vol. 9, Núm. 4, pp. 4395-4410

  4. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

    Therapeutic Advances in Neurological Disorders, Vol. 11

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Male breast cancer in BRCA1 and BRCA2 mutation carriers: Pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

    Breast Cancer Research, Vol. 18, Núm. 1